Unresectable Metastatic Testicular Germ Cell Tumor With Low-grade Neuroglial Neoplasm, Stable After Radiation and Chemotherapy.
Journal
Applied immunohistochemistry & molecular morphology : AIMM
ISSN: 1533-4058
Titre abrégé: Appl Immunohistochem Mol Morphol
Pays: United States
ID NLM: 100888796
Informations de publication
Date de publication:
01 01 2023
01 01 2023
Historique:
received:
01
04
2022
accepted:
12
09
2022
pmc-release:
01
01
2024
entrez:
8
12
2022
pubmed:
9
12
2022
medline:
15
12
2022
Statut:
ppublish
Résumé
We present an 18-year-old male patient who presented with a 16 cm testicular tumor alongside multiple lesions in the lungs, right pelvis with involvement of the ischio/pubic bone, and enlarged pelvic lymph nodes on imaging, suspicious for metastatic disease. Histologic and immunohistochemical examinations revealed an embryonic type neuroectodermal tumor (somatic-type malignancy, 10%) arising in a malignant mixed germ cell tumor composed of teratoma (50%), embryonal carcinoma (10%) and yolk sac tumor (30%). After treatment with chemotherapy and radiation, repeat imaging demonstrated a right pelvic sidewall mass that decreased in size from 40 mm at 11 months after the initial diagnosis to 18 mm at 22 months after the initial diagnosis. A right pelvis medial thigh wall mass that had a lytic bone component showed a slight increase in size from 151 mm at 11 months after the initial diagnosis to 154 mm at 22 months after the diagnosis. On biopsies performed at 3, 10, and 26 months after the initial diagnosis, this lytic lesion consistently demonstrated a neoplasm composed of low-grade neuroglial differentiation. This is the first case in the medical literature where a residual malignant germ cell tumor consisting of low-grade neuroglial neoplasm is in a site that is not amenable to resection without significant morbidity. The tumor initially regressed with the traditional first-line chemo-radiotherapy regimen but regrew and stabilized with a second regimen of chemotherapy. The clinical course of this case invites consideration for an active surveillance approach in cases with similar characteristics.
Identifiants
pubmed: 36476600
doi: 10.1097/PAI.0000000000001081
pii: 00129039-202301000-00007
pmc: PMC9743172
mid: NIHMS1840245
doi:
Types de publication
Case Reports
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
47-50Subventions
Organisme : NCI NIH HHS
ID : T32 CA193145
Pays : United States
Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Matoso A, Idrees MT, Rodriguez FJ, et al. Neuroglial differentiation and neoplasms in testicular germ cell tumors lack immunohistochemical evidence of alterations characteristic of their CNS counterparts: A study of 13 cases. Am J Surg Pathol. 2019;43:422–431.
Murati Amador B, Matoso A. Testicular germ cell tumor showing concurrent PNET and neuroglial neoplasms with wide spectrum of grades. Am J Surg Pathol. 2019;43:865–867.
Flood TA, Ulbright TM, Hirsch MS. “Embryonic-type neuroectodermal tumor” should replace “primitive neuroectodermal tumor” of the testis and gynecologic tract: A rationale for new nomenclature. Am J Surg Pathol. 2021;45:1299–1302.
Speir R, Cary C, Foster RS, et al. Management of patients with metastatic teratoma with malignant somatic transformation. Curr Opin Urol. 2018;28:469–473.
Magers MJ, Kao CS, Cole CD, et al. “Somatic-type” malignancies arising from testicular germ cell tumors: a clinicopathologic study of 124 cases with emphasis on glandular tumors supporting frequent yolk sac tumor origin. Am J Surg Pathol. 2014;38:1396–1409.
Lutke Holzik MF, Hoekstra HJ, Mulder NH, et al. Non-germ cell malignancy in residual or recurrent mass after chemotherapy for nonseminomatous testicular germ cell tumor. Ann Surg Oncol. 2003;10:131–135.
Magers MJ, Perrino CM, Ulbright TM, et al. Immunophenotypic characterization of germ cell tumor-derived primitive neuroectodermal tumors: Evidence for frequent neuronal and/or glial differentiation. Arch Pathol Lab Med. 2021;145:953–959.
Ehrlich Y, Beck SDW, Ulbright TM, et al. Outcome analysis of patients with transformed teratoma to primitive neuroectodermal tumor. Ann Oncol. 2010;21:1846–1850.
Boissonneau S, Duffau H. Identifying clinical risk in low grade gliomas and appropriate treatment strategies, with special emphasis on the role of surgery. Expert Rev Anticancer Ther. 2017;17:703–716.